Yahoo · Aug 14, 2026
KMDA or PRTA: Which Is the Better Value Stock Right Now?
KMDA vs. PRTA: Which Stock Is the Better Value Option?
PR
NASDAQ · PRTA
Prothena Corporation plc Ordinary Shares
Healthcare · Biotechnology
$9.02
Down-$0.28 (-3.01%)
Updated Sep 11, 2026, 4:59 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 556.49M
- P/E ratio
- -1.98
- Dividend yield
- 0.00%
- 52-week range
- $7.73 – $11.80
- Volume
- 310.91K
- Avg. volume
- 643.8K
Price performance
PRTA price history
1M range · 20 trading sessions · Daily adjusted prices
PRTA closed at $9.02 after 20 trading sessions, down 0.66% for the selected period.
- Last close
- $9.02
- Period change
- -0.66%
- Period low
- $8.71
- Period high
- $9.82
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $9.25 | $9.255 | $8.97 | $9.02 | 310.91K |
| Sep 9, 2026 | $9.40 | $9.4958 | $9.22 | $9.30 | 294.56K |
| Sep 8, 2026 | $9.60 | $9.67 | $9.345 | $9.54 | 305.44K |
| Sep 4, 2026 | $9.50 | $9.87 | $9.48 | $9.82 | 383.93K |
| Sep 3, 2026 | $9.77 | $9.78 | $9.5119 | $9.60 | 277.06K |
| Sep 2, 2026 | $9.64 | $9.75 | $9.37 | $9.685 | 341.06K |
| Sep 1, 2026 | $9.28 | $9.63 | $9.26 | $9.61 | 267.67K |
| Aug 31, 2026 | $9.26 | $9.40 | $9.1001 | $9.35 | 335.15K |
| Aug 28, 2026 | $9.02 | $9.479 | $8.95 | $9.33 | 498.12K |
| Aug 27, 2026 | $9.16 | $9.24 | $8.95 | $9.09 | 338.92K |
| Aug 26, 2026 | $9.40 | $9.40 | $9.1533 | $9.25 | 289.04K |
| Aug 25, 2026 | $9.51 | $9.82 | $9.42 | $9.42 | 363.71K |
| Aug 24, 2026 | $9.46 | $9.49 | $9.19 | $9.39 | 248.12K |
| Aug 21, 2026 | $9.11 | $9.52 | $9.09 | $9.45 | 376.04K |
| Aug 20, 2026 | $9.13 | $9.145 | $8.71 | $9.03 | 345.97K |
| Aug 19, 2026 | $8.91 | $9.34 | $8.91 | $9.29 | 385.54K |
| Aug 18, 2026 | $8.88 | $9.00 | $8.58 | $8.71 | 248.56K |
| Aug 17, 2026 | $8.84 | $9.075 | $8.729 | $8.88 | 365.92K |
| Aug 14, 2026 | $9.04 | $9.15 | $8.8387 | $8.86 | 312.6K |
| Aug 13, 2026 | $9.30 | $9.365 | $9.04 | $9.08 | 343.06K |
Latest PRTA news
The latest Smart Investors Daily articles mentioning PRTA.
Stock researchCompany · Overview
PRTA research
Overview
Company profile and research snapshot.
Company profile
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2026 | Citizens | Market Outperform | — |
| Feb 20, 2026 | RBC Capital | Sector Perform | — |
| Dec 1, 2025 | Citizens | Market Outperform | — |
| Nov 7, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Benzinga · Aug 7, 2026
CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of $(1.73) per share from
ChartMill · Aug 7, 2026
Prothena (NASDAQ:PRTA) Beats EPS but Misses Revenue in Mixed Q2 2026 Results
Prothena Q2: revenue $1M misses $28.9M consensus, but adj EPS -$0.32 beats -$0.40. Cost cuts narrow loss; FY cash guidance reiterated.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
